Researchers from Institut d’Investigació Biomèdica de Bellvitge (IDIBELL) have established the epigenetic patterns of breast cancer and also its clinical consequences. The opensource study is published in the journal Molecular Oncology.
Statistics from The Breast Cancer Research Foundation state that nearly 1.7 million new breast cancer cases were diagnosed in 2012. Breast cancer is the second most common cancer in women and men worldwide. In 2012, it represented about 12 percent of all new cancer cases and 25 percent of all cancers in women. Breast cancer is the most frequently diagnosed cancer among women in 140 of 184 countries worldwide.
Globally, breast cancer now represents one in four of all cancers in women. Progress in prevention and early detection, and the use of chemotherapy after surgery (adjuvant chemotherapy), have achieved significantly increase survival in this disease in the last ten years, but much remains to be done.
The identification of patients with high-risk breast cancer is key to knowing whether a patient will require only the removal of the tumour by surgery or whether if they will need additional chemotherapy to make sure the removal of breast cancer cells. Currently, known genetic mutations and expression patterns are determined, but the puzzle of the genetics of the disease remains a large unfinished part.
To address this the researchers analyzed epigenetic alterations, namely the chemical signal called DNA methylation in 500 breast tumours and have compared the patterns obtained with the clinical behaviour of these cancers.
The team note that there are two subgroups of breast tumours by epigenome; one which they have named Epi-Basal, characterized by loss of epigenetic marks causing breakage of chromosomes and the other that the researchers have called Epi-Luminal B, that presents epigenetic inactivation of genes that should protect humans from cancer and the altered cells that can no longer do it.
The researchers highlight that the subtype Epi-Luminal B behaves particularly aggressive form, and is associated with reduced survival of patients. They would therefore recommend that with this class of tumour the medical team avoid surgery and instead administer adjuvant chemotherapy and in those tumours with a more ‘benign’ epigenetic pattern; surgery alone may be curative, thus avoiding the side effects of chemotherapy.
Michelle Petersen is the founder of Healthinnovations, having worked in the health and science industry for over 21 years, which includes tenure within the NHS and Oxford University. Healthinnovations is a publication that has reported on, influenced, and researched current and future innovations in health for the past decade.
Michelle has been picked up as an expert writer for Informa publisher’s Clinical Trials community, as well as being listed as a blog source by the world’s leading medical journals, including the acclaimed Nature-Springer journal series.
Healthinnovations is currently indexed by the trusted Altmetric and PlumX metrics systems, respectively, as a blog source for published research globally. Healthinnovations is also featured in the world-renowned BioPortfolio, BioPortfolio.com, the life science, pharmaceutical and healthcare portal.
Most recently the Texas A&M University covered The Top 10 Healthinnovations series on their site with distinguished Professor Stephen Maren calling the inclusion of himself and his team on the list a reflection of “the hard work and dedication of my students and trainees”.
Michelle Petersen’s copy was used in the highly successful marketing campaign for the mega-hit film ‘Jumanji: The Next Level, starring Jack Black, Karen Gilian, Kevin Hart and Dwayne ‘The Rock’ Johnson. Michelle Petersen’s copywriting was part of the film’s coverage by the Republic TV network. Republic TV is the most-watched English language TV channel in India since its inception in 2017.
An avid campaigner in the fight against child sex abuse and trafficking, Michelle is a passionate humanist striving for a better quality of life for all humans by helping to provide traction for new technologies and techniques within healthcare.